Latest News

Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data
Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data

August 28th 2025

Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.

Enrollment Complete for Phase 2b/3 COMBAT-ALS Study of PDE4 Inhibitor Ibudilast
Enrollment Complete for Phase 2b/3 COMBAT-ALS Study of PDE4 Inhibitor Ibudilast

August 28th 2025

Fully Enrolled CYPRESS Phase 3 Trial to Test Ampreloxetine in Symptomatic Neurogenic Orthostatic Hypotension of MSA
Fully Enrolled CYPRESS Phase 3 Trial to Test Ampreloxetine in Symptomatic Neurogenic Orthostatic Hypotension of MSA

August 28th 2025

Merz’ IncobotulinumtoxinA Begins Phase 3 MINT Trials for Migraine Prevention
Merz’ IncobotulinumtoxinA Begins Phase 3 MINT Trials for Migraine Prevention

August 27th 2025

Zoe Tasma, PhD  (Credit: LinkedIn)
Preclinical Study Reveals Potential of Multireceptor Antagonist to Block CGRP and PACAP

August 27th 2025

Coverage of AAIC 2025

Get direct access to interviews with experts, straight from the conference floor in Vienna, as well as the latest data and clinical news updates.

AAIC 2025

Conference Coverage

View All
ATMRD Congress 2025: Top Expert Interviews and Key Takeaways
ATMRD Congress 2025: Top Expert Interviews and Key Takeaways

August 25th 2025

 Esther Labib-Kiyarash, MSHA, CPHQ
Elevating Patient Perspectives in the Mangement of Parkinson Disease: Esther Labib-Kiyarash, MSHA, CPHQ

August 24th 2025

Exploring Orexin Neuron Loss as an Early Driver of Sleep Disturbances in Alzheimer Disease
Exploring Orexin Neuron Loss as an Early Driver of Sleep Disturbances in Alzheimer Disease

August 22nd 2025

Jennifer Robblee, MD, MSc
Achieving Consensus Definitions for Refractory and Resistant Migraine: Jennifer Robblee, MD, MSc

August 22nd 2025

Video Series
Video Interviews
Podcasts
2 experts are featured in this series.

Most Recent

© 2025 MJH Life Sciences

All rights reserved.